Company Introduction

華上生技醫藥股份有限公司 (簡稱華上生醫，GNT Biotech & Medicals Corporation, GNTbm) 專注在創新藥物研發治療晚期癌症。華上生醫從表觀遺傳調控劑，腫瘤微環境調控劑新藥組合，表觀免疫調控劑，到HDACs 1, 2, 及3 標靶蛋白質降解藥物的研究與開發，一脈相承，聚焦在表觀遺傳學領域，針對晚期及難治性癌症治療的臨床未滿足之需求努力。
 
華上生醫主要的研發核心，包含腫瘤微環境調控新藥組合平台、表觀免疫調控劑平台、及標靶蛋白降解藥物(HPTC, HDACs Proteolysis Targeting Chimera)技術平台為核心研發標的，應用於腫瘤免疫療法的開發。這種全新有效的作用機制之藥物設計及組合，可以有效大幅提升晚期癌症病患治療效益，達到臨床治癒之目標。
 
GNT Biotech and Medicals Corporation (GNTbm) focuses on innovative drug research and development for the treatment of advanced cancer, in the field of epigenetics. GNTbm has devoted to develop new treatment with novel anti-cancer mechanism, better safety and better efficacy to meet the clinical unmet needs of patients with advanced and refractory cancers.

The new drug pipelines ranging from epigenetic modulators, combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a continuously developing progress.

GNTbm’s mission is to become an innovative developer in the field of cancer epigenetics. The application of our new drugs in cancer immunotherapy is dedicated to improve and optimize the therapeutic benefits and quality of life of patients, and give patients with advanced cancers a chance to achieve clinical cure.

Brief description of main products or services 

The main core technologies, including the new drug combination platform for tumor microenvironment regulation, the epigenetic immunomodulation platform and the technology platform of proteolysis target protein degradation drug (HPTC, HDACs Proteolysis Targeting Chimera), are applied for new drug development of cancer immunotherapy. The novel and effective anti-cancer mechanisms based on the design and combinatorial strategy provided through these platforms can effectively improve the therapeutic benefits of treatment for patients with advanced cancer.

Since its establishment GNTbm has been interested in the development of a new-generation epigenetic modulator for cancer treatment, and has partnered with Chipscreen Biosciences, a well-known Chinese new drug company, to develop Chidamide/Tucidinostat for peripheral T cell lymphoma, advanced breast cancer, and other cancer indications. GNTbm-CC-01 is the first new drug combination of tumor microenvironment regulator developed by GNTbm. The drug combination consists of a novel epigenetic modulator Chidamide and a generic drug C. GNTbm-CC-02 has been developed through new formulation of GNTbm-CC-01. It possesses better PK profile and anti-cancer efficacy than GNTbm-CC-01. GNTbm-XX is an epigenetic immunomodulatory agents with novel structure, possessing oral property and excellent immune-regulating activity

GNTbm is devoted to develop new drugs with the goal of fulfilling clinical benefits for patients with advanced or refractory cancers.